UBE2V1 Antikörper (AA 113-145)

Produktnummer ABIN3029435

Produktdetails anti-UBE2V1 Antikörper

Target: UBE2V1 (Ubiquitin-Conjugating Enzyme E2 Variant 1 (UBE2V1))

Bindungsspezifität: AA 113-145

Reaktivität: Human, Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser UBE2V1 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA

Kreuzreaktivität (Details): Expected species reactivity: Rat, Bovine, Chicken, Zebrafish, Xenopus

Aufreinigung: Purified

Immunogen: A portion of amino acids 113-145 from the human protein was used as the immunogen for this UBE2V1 antibody.

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: Titration of the UBE2V1 antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:1000

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: In 1X PBS pH 7.4 with 0.09 % sodium azide

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Aliquot the UBE2V1 antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

Details zu UBE2V1

Target: UBE2V1 (Ubiquitin-Conjugating Enzyme E2 Variant 1 (UBE2V1))

Andere Bezeichnung: UBE2V1 (UBE2V1 Produkte)

Synonyme: CIR1 antikoerper, CROC-1 antikoerper, CROC1 antikoerper, UBE2V antikoerper, UEV-1 antikoerper, UEV1 antikoerper, UEV1A antikoerper, 0610011J09Rik antikoerper, AI256840 antikoerper, D7Bwg1382e antikoerper, CROC-1B antikoerper, ubiquitin conjugating enzyme E2 V1 antikoerper, ubiquitin-conjugating enzyme E2 variant 1 antikoerper, UBE2V1 antikoerper, ube2v1 antikoerper, Ube2v1 antikoerper

Hintergrund: The CROC1 isoforms, also known as UBE2V1, show sequence similarity to ubiquitin-conjugating enzymes (UBCs, or E2s) but lack the conserved cysteine residue critical to catalytic activity of E2s.1 Northern blot analysis detected approximately 2.1- and 2.5-kb CROC1 transcripts in all human tissues examined, with the highest levels in brain, skeletal muscle, and kidney. Partial human intestinal epithelial cell cDNAs have been isolated containing the 3-primecoding sequence and 3-prime untranslated region of UBE2V1, also called UEV1.2 UEV1 does not have ubiquitin-conjugating activity in vitro. UEV1 transcripts are downregulated upon differentiation of a colon carcinoma cell line.1 Constitutive expression of exogenous UEV1 protein in these colon carcinoma cells inhibits their capacity to differentiate upon confluence and induces changes in cell cycle behavior associated with inhibition of CDK1. A heterodimeric protein complex has been identified that links TRAF6 to IKK activation.3 Peptide mass fingerprinting analysis revealed that this complex is composed of the ubiquitin conjugating enzyme UBC13 and the UBC-like protein UBE2V1, also called UEV1A. TRAF6, a RING domain protein, functions together with UBC13/UEV1A to catalyze the synthesis of unique polyubiquitin chains linked through lysine-63 (K63) of ubiquitin. Blockade of this polyubiquitin chain synthesis, but not inhibition of the proteasome, prevents the activation of IKK by TRAF6. These results unveil a new regulatory function for ubiquitin, in which IKK is activated through the assembly of K63-linked polyubiquitin chains.

UniProt: Q13404

Pathways: T-Zell Rezeptor Signalweg, Fc-epsilon Rezeptor Signalübertragung, Activation of Innate immune Response, Toll-Like Receptors Cascades